RxDoctor Payments Data

Andrew Williams, MD

Cardiovascular Disease · Mesa, AZNPI 1548505142

Payments from drug & device makers

$1,007in general payments, 2019–2025

Across 45 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$185
  • Pfizer$148
  • Edwards Lifesciences$145
  • Boston Scientific$95
  • Alnylam Pharmaceuticals Inc.$67
  • E.r. Squibb & Sons, L.L.C.$65
  • plus $302 from 11 others

What the payments were for

  • Food & beverage$1,007100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,007 in reported general payments places this provider in the 30th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$461,184
Medicare patients
1,078
Services billed
4,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban177$179,429
EntrestoSacubitril/Valsartan65$64,458
XareltoRivaroxaban41$57,459
JardianceEmpagliflozin27$29,041
VascepaIcosapent Ethyl21$8,976
Atorvastatin Calcium369$2,833
Rosuvastatin Calcium153$2,538
Metoprolol Succinate223$2,490
Ezetimibe93$1,757
Losartan Potassium163$1,474
Amiodarone Hcl40$1,278
Amlodipine-ValsartanAmlodipine Besylate/Valsartan25$1,028
Amlodipine Besylate167$982
ClopidogrelClopidogrel Bisulfate65$872
Metoprolol Tartrate155$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$179,429177 claims
NovartisEntresto$185$64,45865 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →